Fig. 1From: Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studySustained reduction in exacerbations during benralizumab treatment. Any and severe AER (A) and the percentage of patients without any exacerbations (B) are shown at index date and after 48 and 96 weeks of treatment with benralizumabBack to article page